Presented in part at the 2013 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2013; Chicago, IL; and the 2013 AcademyHealth Annual Research Meeting; June 23-25, 2013; Baltimore, MD.
Impact of state-specific Medicaid reimbursement and eligibility policies on receipt of cancer screening
Version of Record online: 25 AUG 2014
© 2014 American Cancer Society
Volume 120, Issue 19, pages 3016–3024, October 1, 2014
How to Cite
Halpern, M. T., Romaire, M. A., Haber, S. G., Tangka, F. K., Sabatino, S. A. and Howard, D. H. (2014), Impact of state-specific Medicaid reimbursement and eligibility policies on receipt of cancer screening. Cancer, 120: 3016–3024. doi: 10.1002/cncr.28704
We would like to thank Arnold Bragg, PhD, of RTI International for his data programming assistance.
- Issue online: 19 SEP 2014
- Version of Record online: 25 AUG 2014
- Manuscript Accepted: 6 MAR 2014
- Manuscript Revised: 17 FEB 2014
- Manuscript Received: 21 DEC 2013
- access to health care;
- cancer screening;
- health insurance reimbursement;
- health care disparities;
- Papanicolaou test
Although state Medicaid programs cover cancer screening, Medicaid beneficiaries are less likely to be screened for cancer and are more likely to present with tumors of an advanced stage than are those with other insurance. The current study was performed to determine whether state Medicaid eligibility and reimbursement policies affect the receipt of breast, cervical, and colon cancer screening among Medicaid beneficiaries.
Cross-sectional regression analyses of 2007 Medicaid data from 46 states and the District of Columbia were performed to examine associations between state-specific Medicaid reimbursement/eligibility policies and receipt of cancer screening. The study sample included individuals aged 21 years to 64 years who were enrolled in fee-for-service Medicaid for at least 4 months. Subsamples eligible for each screening test were: Papanicolaou test among 2,136,511 patients, mammography among 792,470 patients, colonoscopy among 769,729 patients, and fecal occult blood test among 753,868 patients. State-specific Medicaid variables included median screening test reimbursement, income/financial asset eligibility requirements, physician copayments, and frequency of eligibility renewal.
Increases in screening test reimbursement demonstrated mixed associations (positive and negative) with the likelihood of receiving screening tests among Medicaid beneficiaries. In contrast, increased reimbursements for office visits were found to be positively associated with the odds of receiving all screening tests examined, including colonoscopy (odds ratio [OR], 1.07; 95% confidence interval [95% CI], 1.06-1.08), fecal occult blood test (OR, 1.09; 95% CI, 1.08-1.10), Papanicolaou test (OR, 1.02; 95% CI, 1.02-1.03), and mammography (OR, 1.02; 95% CI, 1.02-1.03). Effects of other state-specific Medicaid policies varied across the screening tests examined.
Increased reimbursement for office visits was consistently associated with an increased likelihood of being screened for cancer, and may be an important policy tool for increasing screening among this vulnerable population. Cancer 2014;120:3016–3024. © 2014 American Cancer Society.